Microsoft has created an open-source fork of Windows Terminal called "Intelligent Terminal," and it allows you to use AI directly inside Terminal without interfering with the regular session.

Pozelimab is the first and only treatment approved for CHAPLE disease, but emerging complement C5 inhibitors offer potential. Currently, there is no cure for CD55 deficiency with Complement ...

C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...

– Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion Refractoriness Currently Planned for 2H 2026 with Potential for Topline Data in 2027 – NEW HAVEN, Conn.--(BUSINESS ...

Gefurulimab showed significant improvements in MG-ADL scores in the phase 3 PREVAIL study for anti-AChR antibody-positive gMG patients. The treatment was well tolerated, with a safety profile ...

The treatment pipeline for generalized myasthenia gravis (gMG) continues to be active, a consequence of the ongoing progress in knowledge that led to approval of six new drugs for the disease. In ...

Dysregulated complement pathways are linked to progression from iAMD to advanced AMD, including NVAMD and GA. Higher systemic levels of C4, C4b, and a reduction in C3 are associated with increased ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

Recent literature suggests that innate immune system effectors may drive poor patient outcomes in acute ischemic stroke (AIS) through complications such as hemorrhagic transformation. Biomarkers for ...